Stake logo

INDP

Indaptus Therapeutics Inc

About INDP

Indaptus Therapeutics, Inc, is a pre-clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Buy US stocks in Australia starting with INDP. Open an account and start investing today!

Market Capitalisation

$14.04M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

9.94K

High today

$1.76

Low today

$1.68

Open price

$1.72

52-week high

$5.47

52-week low

$1.25


INDP FAQs

One share of Indaptus Therapeutics Inc is valued at $1.73.

The ticker symbol for Indaptus Therapeutics Inc is INDP.

To buy INDP stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in INDP

As of 08/02/2023 Indaptus Therapeutics Inc has a market cap of $14M.

The Indaptus Therapeutics Inc 52-week high stock price is $5.47.

The Indaptus Therapeutics Inc 52-week low stock price is $1.25.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.